Loading organizations...
§ Private Profile · Changshu, Jiangxi, China
Cardiovascular medical device manufacturer of artificial heart valves and transcatheter valve systems for heart valve replacement.
KingstronBio, based in Suzhou, China, develops and manufactures cardiovascular medical devices, including artificial heart valves, annuloplasty rings, cardiac patches, and transcatheter valve systems. The company innovates with proprietary technologies such as Micro-Ex™ anti-calcification treatment and AirBo™ dry storage technology, aiming to enhance durability and biocompatibility. Its product portfolio includes the ProStyle M® Transcatheter Mitral Valve System, which completed a two-year First-in-Man study in 10 patients. This system saw its first implantation under pure ultrasound guidance in a national multicenter confirmatory study on March 12, 2026, at Zhongshan Hospital. KingstronBio targets the growing transcatheter mitral valve market, projected to reach $4.66 billion by 2033. The organization was founded in 2012. The firm focuses on cardiovascular medical devices, targeting heart valve replacement markets including the growing transcatheter mitral valve sector.
KingstronBio has raised $66.1M across 2 funding rounds.
KingstronBio has raised $66.1M in total across 2 funding rounds.
KingstronBio has raised $66.1M in total across 2 funding rounds.
KingstronBio's investors include Lu Xiaobao, Guangfa Qianhe, Panglin Investment, Shenzhen Salubris Pharmaceuticals.
KingstronBio has raised $66.1M across 2 funding rounds. Most recently, it raised $47.0M Series C in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 20, 2021 | $47M Series C | LU Xiaobao | Guangfa Qianhe, Panglin Investment | Announced |
| Jan 1, 2021 | $19.2M Series B | Shenzhen Salubris Pharmaceuticals | — | Announced |